Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Repligen Corp RGEN

Technology Scientific & Technical Instruments
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial... see more

Recent & Breaking News (NDAQ:RGEN)

Repligen Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance

GlobeNewswire October 28, 2021

Repligen to Report Third Quarter 2021 Financial Results

GlobeNewswire October 14, 2021

Repligen Announces Agreement to Acquire Avitide Inc.

GlobeNewswire September 16, 2021

Repligen and Navigo GmbH Announce Launch of Industry-First Protein A Ligand for Purification of pH Sensitive Antibodies

GlobeNewswire September 9, 2021

Repligen Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance

GlobeNewswire July 27, 2021

Repligen to Report Second Quarter 2021 Financial Results

GlobeNewswire July 13, 2021

Repligen Corporation Announces Agreement to Acquire Polymem S.A.

GlobeNewswire June 22, 2021

Repligen Corporation to Present at Upcoming Investor Conferences

GlobeNewswire May 25, 2021

Repligen to Report First Quarter 2021 Financial Results

GlobeNewswire April 20, 2021

Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum

GlobeNewswire March 17, 2021

Repligen Corporation to Present at Barclays Global Healthcare Conference

GlobeNewswire March 3, 2021

Repligen Reports Fourth Quarter and Full Year 2020 Financial Results

GlobeNewswire February 24, 2021

Repligen Corporation to Present at 10th Annual SVB Leerink Healthcare Conference

GlobeNewswire February 22, 2021

Repligen to Report Fourth Quarter and Full Year 2020 Financial Results

GlobeNewswire February 11, 2021

Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines

GlobeNewswire February 8, 2021

Repligen Corporation to Present at 39th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2021

Repligen Corporation Announces Closing of Public Offering of $312.2 Million, Including Full Exercise of Underwriters' Option

GlobeNewswire December 10, 2020

EC Mergers & Acquisitions advised ARTeSYN on its Sale to Repligen

PR Newswire December 8, 2020

Repligen Corporation Prices Public Offering of Shares of Common Stock

GlobeNewswire December 7, 2020

Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock

GlobeNewswire December 7, 2020